Potassium Chloride
drugOn this page
Also known as B1653Chloride (as potassium)Diffu-kDuro-kE 508E-508E508INS NO.508INS-508K+10K+8K-continK-dur 20K-leaseK-tabKaleoridKaleorid lpKali muriaticumKalii chloridumKaon cl
Summary
Potassium Chloride (CHEMBL1200731) is an approved small molecule (ATC A12BA51); indicated across 17 conditions including hypertensive disorder and heart failure.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A12BA51 (+2 more)
- Indications: 17 conditions
- Clinical trials: 20
- Chemistry: 74.55 Da · ClK
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200731 |
| Name | Potassium Chloride |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 4873 |
| ChEBI | CHEBI:32588 |
| ATC | A12BA51, A12BA01, B05XA01 |
| Molecular formula | ClK |
| Molecular weight | 74.55 |
| InChIKey | WCUXLLCKKVVCTQ-UHFFFAOYSA-M |
SMILES: [Cl-].[K+]
IUPAC name: potassium chloride
ChEBI definition: A metal chloride salt with a K(+) counterion.
Other ChEBI roles (chemical / environmental): fertilizer, NMR chemical shift reference compound.
Also known as: B1653, Chloride (as potassium), Diffu-k, Duro-k, E 508, E-508, E508, INS NO.508, INS-508, K+10, K+8, K-contin
Parent form; salt/anhydrous children: CHEMBL2105895
Patent coverage: 164,096 distinct patent families (396,239 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 396,124 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Carbonic anhydrase 4.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
17 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hypertensive disorder | 3 | MONDO:0005044 | EFO:0000537 |
| heart failure | 3 | MONDO:0005252 | EFO:0003144 |
| congestive heart failure | 3 | MONDO:0005009 | EFO:0000373 |
| myocardial infarction | 3 | MONDO:0005068 | EFO:0000612 |
| heart disorder | 3 | MONDO:0005267 | EFO:0003777 |
| intermediate coronary syndrome | 3 | MONDO:0006805 | EFO:1000985 |
| constipation disorder | 3 | MONDO:0002203 | HP:0002019 |
| coronary artery disorder | 3 | MONDO:0005010 | EFO:0001645 |
| brain neoplasm | 2 | MONDO:0021211 | EFO:0003833 |
| diastolic heart failure | 2 | MONDO:0006727 | EFO:1000899 |
| aortic valve stenosis | 2 | MONDO:0042981 | EFO:0000266 |
| cardiac arrest | 2 | MONDO:0000745 | EFO:0009492 |
| toxic shock syndrome | 1 | MONDO:0001881 | EFO:0006834 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 20.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 9 |
| Not specified | 6 |
| PHASE4 | 3 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01085071 | PHASE4 | COMPLETED | Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients |
| NCT01818583 | PHASE4 | COMPLETED | Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter |
| NCT02015962 | PHASE4 | UNKNOWN | Comparison of Enteral Versus Intravenous Potassium Supplementation |
| NCT00241839 | PHASE3 | COMPLETED | Uric Acid and Hypertension in African Americans |
| NCT04913805 | PHASE2 | RECRUITING | Matching Perfusion and Metabolic Activity in HFpEF |
| NCT05138575 | PHASE2 | RECRUITING | SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial |
| NCT07238400 | PHASE2 | RECRUITING | Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia |
| NCT00913796 | PHASE2 | COMPLETED | Metabolic Acidosis in Renal Transplant Patients |
| NCT01074918 | PHASE1/PHASE2 | WITHDRAWN | Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients |
| NCT02256345 | PHASE2 | COMPLETED | Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF |
| NCT02450773 | PHASE2 | WITHDRAWN | Prevention of Severe Postpartum Hypertension |
| NCT03483051 | PHASE2 | COMPLETED | Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS) |
| NCT03627130 | PHASE2 | COMPLETED | The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy |
| NCT04316611 | PHASE2 | WITHDRAWN | Potassium Chloride in Out-of-hospital Cardiac Arrest Due to Refractory Ventricular Fibrillation |
| NCT03253172 | Not specified | ACTIVE_NOT_RECRUITING | Potassium Supplementation in CKD |
| NCT00224939 | Not specified | TERMINATED | Pre-ESRD Syndrome in High Risk African Americans |
| NCT00357214 | Not specified | COMPLETED | Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults |
| NCT02982356 | Not specified | UNKNOWN | Prenatal Screening, Diagnosis and Intrauterine Intervention of Fetal Abnormal Chromosome and Structure in Twins Pregnancy |
| NCT04755400 | Not specified | COMPLETED | The Effect of Orally Administrated Nitrate on Renal Parameters and Systemic Haemodynamics |
| NCT05758142 | Not specified | TERMINATED | Potassium Intake-response Trial to Control Hypertension |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).